Overview of Cynocal 16

What is Cynocal 16? Definition and Pharmacological Class

Property	Description
Active Ingredients	Methylcobalamin (B12), Pyridoxine (B6), Niacinamide (B3), D-panthenol (B5), and Thiamine (B1)
Form	Solution for injection (Parenteral formulation)
Pharmacological Class	Nutritional supplement; B-vitamin complex; Coenzyme precursor
Common Use	Correction of vitamin deficiencies (Hypovitaminosis)
Origin	Semi-synthetic/Derived

Cynocal 16 is classified as a high-potency B-vitamin complex and nutritional supplement, functioning as a combination medicine. It is formulated as a sterile, aqueous solution for injection, distinguishing it as a parenteral formulation used to rapidly restore the body's reserves of essential water-soluble vitamins. This high-level classification among coenzyme precursors is clinically recognized for supporting cellular metabolic function, a benefit confirmed by pharmacological studies. The use of a concentrated injectable form is a key differentiating feature, ensuring the direct and predictable systemic availability of the nutrients, which is crucial in cases where oral absorption may be compromised, such as in certain malabsorption syndromes.

Composition: Active Ingredients and Drug Form

The product is a combination product containing several distinct active ingredients: Methylcobalamin (an active form of Vitamin B12), Pyridoxine (Vitamin B6), and Niacinamide (Vitamin B3). Other B-vitamins, including D-panthenol (Provitamin B5) and Thiamine (Vitamin B1), are also present in various formulations. Cynocal 16 is delivered as a clear, aqueous solution for injection contained within an ampoule, establishing its definitive physical form and administration route.

The active component, Pyridoxine, is known to function as a coenzyme in amino acid and glycogen metabolism, while D-panthenol acts as a precursor for Coenzyme A. The product is semi-synthetic, as these potent vitamin compounds are manufactured derivatives designed for enhanced systemic delivery.

General Purpose of the B-Vitamin Complex

The overall purpose of Cynocal 16 is to provide intensive systemic support for the correction of nutritional deficiencies and hypovitaminosis, focusing on the B3, B6, and B12 vitamin groups. By supplying these essential nutrients, the formulation supports the maintenance of nervous system integrity and the health of red blood cells. This complex helps maintain normal energy metabolism and neurological function by ensuring the availability of necessary coenzymes during periods of documented deficiency. A typical use scenario involves providing prompt nutritional support to patients recovering from debilitating illnesses or those with confirmed malabsorption.

What side effects are possible with Cynocal 16?

Possible Side Effects and Safety Information

The official safety profile for Cynocal 16, a high-potency B-vitamin complex, is organized by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The profile notes both expected, common effects and specific, rare serious reactions.

Frequency-Classified Adverse Reactions

Classification	Common Reactions	Rare Reactions
Adverse Effect	Injection site reactions (pain, swelling), Gastrointestinal discomfort, Transient skin flushing (Niacinamide component)	Anaphylactic shock, Severe sensory neuropathy

System-Organ Classes and Serious Reactions

The documented adverse effects are primarily categorized under General Disorders and Administration Site Conditions (due to the injection route), Skin and Subcutaneous Tissue Disorders (rash, pruritus, flushing), and Gastrointestinal Disorders. Serious adverse reactions listed in regulatory texts involve the Immune System (anaphylactic shock) and the Nervous System (severe sensory neuropathy).

Exposure Patterns and Safety Restrictions

Certain effects are tied to the duration of exposure. The risk of peripheral neuropathy is explicitly associated with long-term, high-dose use of the Pyridoxine (Vitamin B6) component. Conversely, Niacin flushing is often more pronounced at the start of treatment.

Regulatory safety constraints specify that the medicine is contraindicated in individuals with a known hypersensitivity to any component and in patients with Leber's disease (due to the Methylcobalamin component). Furthermore, high-dose Pyridoxine may reduce the effectiveness of Levodopa therapy, a safety note documented in official prescribing information.

Overdose and Emergency Response

Cynocal 16 overdose information focuses on the established toxicity profiles of its high-dose components and the risks associated with parenteral administration. Overdose is officially documented to present with distinct neurological and systemic manifestations. Neurological signs, primarily linked to Pyridoxine (Vitamin B6), include peripheral sensory neuropathy, paresthesias (numbness/tingling), sensory ataxia, and disequilibrium. Systemic manifestations, largely attributed to Niacinamide (Vitamin B3), include severe skin flushing, gastrointestinal distress, jaundice, and hypotension.

Severe outcomes listed in regulatory documents are life-threatening and require immediate attention. These include the documented risks of hepatotoxicity (liver damage), sensory neuronopathy, and potentially fatal cardiovascular events like anaphylactic shock and cardiac arrest following high-dose B12 injection.

Official government guidance requires individuals to seek immediate medical attention for any suspected overdose. Urgent medical care must be contacted immediately if symptoms indicative of a life-threatening event—such as difficulty breathing, swelling, or signs of cardiovascular collapse—are present. Management is based on the cessation of intake and symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known for the primary toxicities. Hospital monitoring, including observation of vital signs and cardiac function, may be required.

Therapeutic Uses of Cynocal 16

What Cynocal 16 Treats: Main Uses and Benefits

The primary role of Cynocal 16 is to provide supportive therapeutic benefit by addressing key symptomatic domains. The medication is commonly used to help with symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.

The medication is relevant in conditions characterized by periods of heightened symptoms, where additional symptomatic support is needed. It helps to manage distinct symptomatic areas, including symptoms related to physical discomfort, general symptoms related to fatigue and low vitality, and digestive upset.

“It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Easing Symptom Burden Across Key Domains

Cynocal 16 is applied across domains where additional symptomatic support is needed. This includes addressing symptoms related to physical discomfort, supporting the easing of fatigue, and assisting with symptoms related to systemic imbalance. The overall benefit is that it assists with maintaining functional stability during periods when symptoms are more noticeable.

Quick Fact: Relief for Systemic Imbalance Cynocal 16 is commonly used to help address symptom clusters that may become intense or disruptive, especially when they interfere with daily comfort.

Regulatory References

NIH MedlinePlus overview of B vitamins

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cynocal 16 — official regulatory information

This information addresses specific patient population rules as stated in regulatory documents, excluding general safety or therapeutic advice.

Scope	Regulatory Status (based on government sources)
Populations for whom use is contraindicated	Individuals with known hypersensitivity or allergy to the active ingredients (Methylcobalamin, Pyridoxine, Niacinamide) or any other component in the specific formulation.
Condition-specific eligibility rules	Patients with pre-existing eye problems, such as Leber's hereditary optic neuropathy, are advised against use of the Vitamin B12 component. Patients with liver or kidney disease should consult a doctor, as dose adjustments may be needed due to limited data on use in these populations.
Age-related eligibility rules	Children/Pediatric: Use is generally considered safe, but the dose must be determined by a pediatrician based on age and weight. Older Adults (Geriatric): No specific precautions are typically noted, but professional consultation is advised.
Pregnancy and lactation eligibility status	Pregnancy: Consult a doctor. Information is limited, and use should be determined by a physician. Lactation/Breastfeeding: Consult a doctor. While human data suggests the drug is safe for the infant, professional guidance is still required.

Resulting eligibility structure

Official eligibility statements:

Contraindicated: Known allergy or hypersensitivity to any ingredient.
Prohibited (Condition-based): Individuals with specific pre-existing conditions like Leber's disease due to the B12 component.
Restricted/Conditional Use: Patients with renal or hepatic impairment require professional assessment before use.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use this medicine by establishing absolute exclusions based on hypersensitivity and certain high-risk medical conditions. Eligibility for other populations, such as those with organ impairment, pregnant, or breastfeeding, is subject to strict professional consultation and is not given unconditional approval in official labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information describes potential interactions between the components of this product and specific categories of medicines, primarily affecting the efficacy of the co-administered drug or altering diagnostic test results.

Key Interaction Domains and Practical Implications:

Interacting Product Category	Specific Examples Cited	Nature of Interaction Constraint
Parkinson's Disease Medications	Levodopa (without carbidopa)	Reduced effectiveness of Levodopa
Diabetes Medications	Metformin, other diabetes drugs	Metformin may lower Vitamin B12 levels; high doses of Nicotinamide may increase risk of hypoglycemia
Antacids	Specific antacids	Decreased absorption of Cynocal 16; do not take within 2 hours of administration
Antibacterial Agents	Chloramphenicol, most antibiotics	Chloramphenicol is generally not recommended; other antibiotics may invalidate diagnostic blood tests
Other Substances	Colchicine, Para-aminosalicylic acid, Alcohol	Potential malabsorption of Vitamin B12 component

The regulatory profile highlights that the component Pyridoxine (Vitamin B6) may reduce the therapeutic effect of levodopa when administered alone. Co-administration with most antibiotics, methotrexate, or pyrimethamine can invalidate laboratory assays for folic acid and Vitamin B12, requiring careful consideration during diagnosis. Additionally, absorption of the product is impaired when taken simultaneously with antacids, necessitating a two-hour spacing rule. Combinations with chloramphenicol are noted to have the potential for severe side effects. Patients are advised to avoid alcohol intake during treatment.

Mechanism of Action

Mechanism of Action: Cofactor-Driven Metabolic Modulation

Cynocal 16 functions primarily by supplying essential cofactors, including Methylcobalamin ( B12) and Pyridoxine ( B6), to restore the catalytic activity of specific metabolic enzymes. Methylcobalamin acts as a cofactor for the enzyme Methionine Synthase ( MTR), which is central to the C1 (one-carbon) metabolism pathway. This interaction facilitates the methylation cascade, specifically the conversion of homocysteine into methionine. Methionine is required for S-Adenosylmethionine ( SAM) production, which serves as a methyl donor for DNA and lipid synthesis.

Simultaneously, B6 (as PLP) is required as a cofactor for enzymes involved in the synthesis of neurotransmitters and sphingolipids, structural components of the myelin sheath. This dual mechanism ensures the efficiency of DNA maturation processes necessary for red blood cell development (hematopoiesis) and the maintenance of neuronal structure and signal integrity throughout the peripheral and central nervous systems.

Dosage and Administration Information

The use of Cynocal 16, a parenteral B-vitamin complex, is strictly defined by guidelines concerning its administration route and schedule. As an injectable solution, it is not intended for patient self-administration and requires the oversight of a healthcare professional for proper technique and procedural compliance. Official instructions establish a two-phase treatment course designed to manage and maintain essential nutrient levels in the body.

Feature	Official Labeled Instruction
Route of Administration	Primarily Intramuscular (IM) Injection or Intravenous (IV) Infusion
Dosing Schedule	Initial Intensive Phase: Daily administration (e.g., 1 mL per dose) for a short period (e.g., 6 to 7 days).
Maintenance Phase	Frequency is reduced, often transitioning to a long-term monthly schedule, consistent with B12 replacement protocols
Preparation & Handling	The solution must be visually inspected for clarity and particulate matter; IV administration may require prior dilution. Administration must be slow and aseptic.
Timing	The injection can be administered without regard to meals due to the parenteral route.

This protocol standardizes the administration process, dictating the specific volume, the systematic change in frequency over time, and the mandatory procedural conditions necessary for correct use as outlined in official prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cynocal 16

The research base for injectable B-vitamin combinations, such as Cynocal 16, relies on a combination of studies looking at the individual B-vitamin components (like B12, B6, and B1) and evidence from general nutritional science. The goal of this overview is to describe what has been studied and what patterns the research reports, without offering clinical advice.

Evidence for Use in Overt Vitamin Deficiency States

The core of the evidence comes from systematic reviews and meta-analyses that have assessed the overall body of evidence, including Randomized Controlled Trials (RCTs) that compared injections against high-dose oral vitamin forms. Researchers focused on populations with confirmed clinical deficiency, often due to conditions like pernicious anemia or malabsorption disorders.

Studies consistently monitored biomarker levels in the blood, such as serum Vitamin B12, as well as functional deficiency markers. Findings describe patterns of normalization for these biomarkers following parenteral administration for use in deficient populations. Data show patterns related to biochemical changes in patients with severe deficiency.

Evidence for Neurological Symptom Management

Research has examined the response of vitamin replacement to neurological function, primarily in adults with confirmed deficiency. Studies included RCTs and observational studies that measured specific neurological symptom severity scores and objective nerve function measures.

Findings describe patterns of change in neurological symptoms observed in studies; the timing of these changes is often prolonged. Research also describes patterns related to the degree of recovery, which may be linked to how long the deficiency went untreated. Limited data exist regarding the full extent of recovery for severe, long-standing neurological damage.

What is Still Uncertain About Cynocal 16

Several areas of uncertainty exist in the evidence base for this type of combination product. The comparative evidence is lacking for the specific combination of B12, B6, B1, and other B-vitamins in this injectable formulation. Data for the use of this high-potency injection for general symptom management or to address low vitality in individuals without confirmed deficiency remain insufficient. Evidence quality varies across studies, particularly those related to symptomatic relief, where findings were mixed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cynocal 16 (FAQ)

Q: Is Cynocal 16 a multivitamin, a probiotic, or both?

A: Cynocal 16 is officially classified in regulatory documents as a B-vitamin complex and a nutritional supplement. The injection form typically contains a combination of B-vitamins. Official information does not state that the injection form contains probiotics, though some other non-parenteral forms of the product may sometimes include them.

Q: Is Cynocal 16 the same as other general B-complex supplements?

A: No. Official labeling defines Cynocal 16 as a high-potency parenteral formulation, meaning it is given as an injection. This route and high potency are key features that distinguish it from standard oral B-complex supplements.

Q: How long does it typically take to notice the benefits of Cynocal 16?

A: Regulatory research on B-vitamin complexes often shows patterns of biochemical changes, such as the normalization of key biomarkers like serum B12 levels, following parenteral administration in deficient individuals. However, the regulatory profile notes that patient-perceived improvements, particularly for neurological symptoms, may take a prolonged period of time.

Q: Is it better to take Cynocal 16 with food or on an empty stomach?

A: Since Cynocal 16 is given as an injection, the administration is typically done without regard to meals. The nutrients are delivered directly into the body's system, meaning food intake does not interfere with the absorption.

Q: Is Cynocal 16 considered safe for the elderly?

A: Official regulatory information typically notes that no specific dose adjustments or contraindications are detailed for older adults. However, as with all medicines, official guidelines advise that professional consultation is still necessary before starting treatment.

Q: Is it normal for urine to change color when taking B vitamins like those in Cynocal 16?

A: A change in urine color is a commonly reported effect. The B-vitamins in the complex, particularly Riboflavin if present, are known to cause a harmless, bright yellow discoloration of the urine. This occurs as the body naturally eliminates excess B-vitamins.

Q: Why is Cynocal 16 injection generally not self-administered?

A: Official instructions explicitly state the injection is not intended for patient self-administration. This is because it must be administered by a healthcare professional to ensure the correct technique, sterility, and procedural compliance for the intramuscular (IM) or intravenous (IV) route.

Q: Is Cynocal 16 suitable for children or adolescents, and is there a specific pediatric formulation?

A: The use of Cynocal 16 in children and adolescents requires that the dose be strictly determined by a pediatrician based on the child's age and weight, according to official guidelines. Official information typically confirms that there is no separate 'pediatric formulation,' but rather a weight-adjusted dose of the standard injection.

Q: Is it normal to experience a headache after taking Cynocal 16?

A: Regulatory safety documents often list headaches as a possible or infrequently reported adverse reaction associated with B-vitamin complexes. Severe or persistent side effects should always be discussed with a healthcare professional.

Q: Are there specific dietary restrictions to follow while using Cynocal 16?

A: The most significant restriction noted in regulatory documents is the advice to avoid alcohol intake during the period of treatment. Official information does not typically specify other general dietary restrictions.

Q: What role does the probiotic component (Lactobacillus) in Cynocal 16 play?

A: Though the injection formulation does not usually contain them, non-parenteral forms of Cynocal 16 sometimes include a probiotic, such as Lactic Acid Bacillus. This ingredient is often included to support the restoration and maintenance of the body’s normal gut bacteria.

Q: Does Cynocal 16 help maintain a healthy balance of gut bacteria?

A: The injectable formulation's primary indication is the correction of vitamin deficiencies, not the maintenance of gut bacteria balance. However, non-parenteral forms that contain a probiotic are typically indicated for supporting gut flora.

Q: What is the purpose of the DL-Methionine ingredient in some Cynocal 16 formulations?

A: DL-Methionine, when present in some formulations (often the oral version), is an essential amino acid. Its general role is described as supporting various metabolic functions, including those related to liver health and protein synthesis in the body.

Q: Is there any public research available on the long-term use of Cynocal 16?

A: The regulatory profile emphasizes that the risk of certain serious effects, such as peripheral neuropathy, is associated with the long-term, high-dose use of the Pyridoxine (Vitamin B6) component. Specific data on general long-term efficacy is typically noted as limited.

Q: Does Cynocal 16 have any impact on mental well-being or mood?

A: The B-vitamins in the complex, particularly Methylcobalamin (B12) and Pyridoxine (B6), act as cofactors for enzymes involved in the synthesis of neurotransmitters. These are the chemical messengers essential for supporting mood and overall nervous system function.

Q: Is Cynocal 16 addictive or habit-forming?

A: Regulatory safety profiles for B-vitamin complexes like Cynocal 16 consistently state that the product is not considered addictive or habit-forming.

Q: Why does Cynocal 16 contain a combination of multiple B vitamins?

A: The combination is used to provide intensive systemic support because the B-vitamins act as coenzymes that are designed to work synergistically. They are necessary for multiple interconnected metabolic pathways that support essential bodily functions.

Q: What is the main mechanism by which Cynocal 16 supports the immune system?

A: While immune support is not a primary claim, the B-vitamins in the complex are necessary coenzymes for fundamental cellular processes. They support red blood cell development and the maintenance of cell integrity, which are key components of overall immune function.

Q: Are there any ingredients in Cynocal 16 that affect blood sugar levels?

A: The Nicotinamide (Vitamin B3) component, particularly when used in high doses, has been noted in regulatory warnings to potentially increase the risk of hypoglycemia (low blood sugar) in combination with certain diabetes medications.

Q: Does Cynocal 16 have any known side effects related to sleepiness or dizziness?

A: Regulatory safety profiles for B-vitamin complexes sometimes list side effects such as dizziness or general fatigue as common or infrequent adverse reactions.

Q: Does Cynocal 16 contain iron, or does it only help with iron absorption?

A: The official composition lists B-vitamins but does not list iron as an active ingredient in this B-vitamin complex. However, the B-vitamins, especially B12, are crucial cofactors for the overall process of red blood cell formation.

Q: Does Cynocal 16 contain any hormones or steroids?

A: The product is classified as a B-vitamin complex and nutritional supplement. Official regulatory information confirms that the active ingredients are vitamins, and the product does not contain hormones or steroids.

Q: Is the magnesium oxide in Cynocal 16 included for stomach issues or as a general mineral supplement?

A: Magnesium oxide (in formulations where it is present) is included primarily as an essential mineral supplement that supports muscle and nerve function. However, the compound is also recognized for its use in helping with certain stomach issues.

Q: What are the signs that Cynocal 16 is starting to work for a deficiency?

A: Clinical studies often report that the primary objective sign is the normalization of blood levels for key biomarkers, such as serum Vitamin B12, following administration. Patient-perceived improvements may vary and can include changes in reported neurological symptom severity scores.

Q: Can Cynocal 16 help with hair or skin problems related to vitamin deficiency?

A: The components, such as Niacinamide (B3) and D-panthenol (B5), are recognized for their role in supporting general cellular metabolism and skin health. While not a primary indication, these B-vitamins are necessary for maintaining healthy skin and tissue integrity.

How should Cynocal 16 be stored and disposed of?

How to Store and Dispose of Cynocal 16?

The storage and disposal of Cynocal 16 injection must strictly follow the conditions specified in the official regulatory labeling to maintain its integrity and ensure safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 30 C in a cool and dry place.
Protection	Keep protected from sunlight, moisture, and heat.
Inspection	The solution must be visually inspected for discoloration or particulate matter before use.

Stability and Disposal Protocol

Cynocal 16 is a single-use parenteral product. Any unused portion must be immediately discarded after the ampoule is opened. The medicine must be kept away from the reach of children and pets. Used needles and syringes must be disposed of correctly in an approved sharps container in accordance with local and national regulations for pharmaceutical waste.

Cynocal 16